Although the correlation between aberrant expression of Tn/STn antigens and tumor progression has been widely demonstrated and the technical barriers to generating specific monoclonal antibodies have been largely overcome, the spatiotemporal specificity of its regulatory network remains to be elucidated, and Tn/STn-based liquid biopsy techniques are still challenged by glycoepitope heterogeneity and low abundance. The gene discussed is EEF1A2; the disease is neoplasm.